AbbVie Inc.

New York Stock Exchange

Articles

63
Show Summary
Show Bulletpoints
Detailed View
Neutral 0

AbbVie (NYSE:ABBV) Expands Awareness And Psychedelic Research Russell 1000

The provided text indicates that AbbVie, identified by its New York Stock Exchange ticker ABBV, is involved in an initiative to expand awareness and conduct psychedelic research. However, the specific details regarding this program are obscured because the content of the article appears to be inaccessible behind a login wall or subscription paywall on the Kalkine Media platform. The visible text includes standard website navigation prompts, such as instructions for users to log in, create an account, or submit a form to continue reading the full story. The surrounding context provided in the snippet suggests this news item is part of a broader healthcare and pharmaceutical sector update published on March 25, 2026, at 01:15 PM PDT. While other headlines are visible alongside the AbbVie entry—mentioning Transocean reaching an annual peak, Gray Media expanding its NYSE presence, AstraZeneca gaining momentum, and Teleflex rallying after an upgrade—the actual details of AbbVie's specific research activities, financial implications, or strategic motivations for entering psychedelic space are not disclosed in this excerpt. Furthermore, the remainder of the text is dedicated to legal disclaimers and terms regarding data submission. It confirms that by proceeding on the site, users consent to be contacted by Kalkine Media representatives for marketing purposes, including telemarketing calls or emails from Kalkine group entities. No specific numerical data, dates beyond the publication timestamp, or quotes from company executives are included in this accessible portion of the news feed.

🏛 AbbVie expands psychedelic research within the Russell 1000 index.

💊 Healthcare evolves through scientific innovation and therapeutic diversification.

🔒 Access full content via free account registration or form submission.

✅ Registration confirms consent for marketing communications from Kalkine Media.

🏛️ AbbVie (NYSE:ABBV) is expanding its awareness and psychedelic research initiatives within the Russell 1000 index context.

💊 The healthcare sector is evolving through scientific research, public engagement, and therapeutic diversification.

⚡ A combination of established pharmaceutical capabilities and new research avenues reflects this blend.

🔒 Readers must log in, create a free account, or fill out a form to access the full article content.

✅ By submitting details, users confirm consent for Kalkine Media representatives to contact them regarding marketing offers and discussions.

📞 Contact methods include email and phone calls made by Kalkine group's telemarketing entities on behalf of the publisher.

Bullish Signals
  • No meaningful points found.
  • Input array is empty.
  • Unable to condense content.
  • Missing data for processing.
  • List contains no items.
Bullish Signals
Risk Factors
  • The provided article is a promotional landing page and not substantive financial news; it contains no actual negative points, risks, or data about AbbVie.
  • The text lists unrelated positive headlines for competitors like Transocean (NYSE:RIG) and AstraZeneca (NYSE:AZN), but offers no information on AbbVie's specific operational or financial challenges.
Somewhat Bullish +45

LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?

The analysis compares Eli Lilly (LLY) and AbbVie (ABBV) as leading U.S. drugmakers with significant market capitalizations, strong R&D pipelines, and presence in key areas like immunology, oncology, and neuroscience. Eli Lilly's growth is heavily driven by its GLP-1 therapies, Mounjaro and Zepbound, which generated combined sales of $36.5 billion in 2025, accounting for approximately 56% of total revenues. The company has secured approvals for multiple new therapies including Omvoh, Jaypirca, Ebglyss, and Kisunla, with expectations that these alongside Mounjaro, Zepbound, Inluriyo, and Orforglipron will drive 2026 sales growth. Lilly is focusing on expanding into oral GLP-1 treatments via orforglipron, anticipated for U.S. launch in the second quarter of 2026, aiming to counter the first-to-market advantage gained by Novo Nordisk with its oral Wegovy pill approved in December 2025 and launched in January 2026. Additionally, Lilly is diversifying beyond GLP-1 into cardiovascular, oncology, and neuroscience, having announced several M&A deals in 2025 to broaden its therapeutic footprint. AbbVie is positioned differently, primarily through its successful transition following the loss of exclusivity on Humira, which previously accounted for over 50% of revenues. Its immunology portfolio, consisting of Skyrizi and Rinvoq, generated combined sales of $26.0 billion in 2025 with growth exceeding 40%, and the company projects 2026 sales of more than $31 billion, slightly higher than its long-term guidance for 2027. Other segments are also performing well; neuroscience revenues rose nearly 20% to $10.8 billion in 2025 driven by Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta, while oncology contributed $6.6 billion with contributions from Venclexta, Elahere, and Epkinly offsetting declines in Imbruvica. To fuel long-term growth, AbbVie has pursued an acquisition strategy, investing over $5 billion in 2025 to acquire assets in immunology, oncology, and neuroscience. Despite strong fundamentals, both companies face distinct challenges that could impact their upside potential in 2026. Eli Lilly faces pressure from declining product prices in the United States, which is expected to drag top-line growth by low to mid-teens percentages in 2026, alongside rising competition in the GLP-1 diabetes and obesity market and flat-to-down sales for late-life cycle products like Trulicity, Taltz, and Verzenio. AbbVie continues to navigate the post-Humira landscape but relies on continued strong performance from Skyrizi and Rinvoq. Both companies maintain extensive global reach and diverse pipelines, making them attractive investment options, though Lilly appears more reliant on obesity growth while AbbVie has successfully diversified into aesthetics and eye care beyond its immunology core. The ultimate investment choice depends on weighing Lilly's explosive but potentially price-constrained GLP-1 momentum against AbbVie's robust diversification across multiple high-growth segments with a proven ability to replace blockbuster revenue losses.

📊 Eli Lilly GLP-1 drugs generated $36.5B in 2025 sales representing over half its revenue.

💼 AbbVie's Skyrizi and Rinvoq hit $26B combined sales, exceeding 2027 guidance for 2026.

🚀 Both companies expect key drug growth despite price declines and legacy product revenue drops.

⚡ Lilly launches oral GLP-1 in Q2 2026; AbbVie acquired $5B+ assets to expand pipelines.

⚖ Strong balance sheets support both firms diversifying into neuroscience, oncology, and cardiovascular markets.

🔍 The article compares Eli Lilly (LLY) and AbbVie (ABBV) as top contenders for investment upside in 2026.

💊 Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $36.5 billion in 2025 sales, representing over half of its total revenue.

🚀 Both companies' GLP-1 or other key drug sales are expected to continue growing into 2026 despite potential market headwinds.

💼 AbbVie successfully navigated Humira's patent loss with Skyrizi and Rinvoq, which generated $26 billion in 2025 combined sales.

📈 Lilly expects its approved pipeline drugs including orforglipron to drive further growth and offset declining legacy product revenues.

🗓️ Lilly plans to launch its oral GLP-1 pill orforglipron in the US during the second quarter of 2026 to compete with Novo Nordisk's recent oral Wegovy.

⚠️ Price declines for Lilly's products in the US and rising competition are expected to impact top-line growth by a low to mid-teens percentage in 2026.

💰 AbbVie expects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026, surpassing its long-term guidance target for 2027.

🧠 AbbVie's neuroscience portfolio drove revenue growth with nearly $20% increase to $10.8 billion in 2025 led by Botox and migraine drugs.

⚖️ Lilly is diversifying beyond obesity into cardiovascular, oncology, and neuroscience areas through M&A deals announced in 2025.

🏥 AbbVie acquired over $5 billion worth of early-stage assets in 2025 to bolster its immunology, oncology, and neuroscience pipelines.

📉 Both companies face legacy product declines but maintain strong balance sheets and global reach across key therapeutic areas.

🧬 Lilly is developing retatrutide, a triple-acting incretin for obesity and diabetes, alongside other indications in late-stage studies.

⚙️ AbbVie's oncology segment grew 1.5% year-over-year to $6.6 billion in 2025 despite some decline in key product Imbruvica sales.

🌍 Both firms have extensive global operations with strong presence in immunology, oncology, and neuroscience markets.

Bullish Signals
  • Skyrizi and Rinvoq generated $26.0 billion in 2025 sales with over 40% growth.
  • Combined Skyrizi/Rinvoq 2026 sales expected to exceed $31 billion targets.
  • Neuroscience portfolio sales surged nearly 20% to $10.8 billion in 2025.
  • On oncology generated $6.6 billion in 2025, up 1.5% year over year.
  • AbbVie invested over $5 billion in 2025 acquisitions for long-term pipeline growth.
  • Lilly's new drugs including Mounjaro and Ebglyss will drive 2026 sales.
  • Multiple Lilly therapies like Kisunla and Omvoh recently received regulatory approvals.
  • Lilly's orforglipron oral GLP-1 launches Q2 2026 as injectable alternative.
Risk Factors
  • Declining US drug prices expected to drag growth by low-mid teens in 2026.
  • Late-cycle sales of Trulicity, Taltz, and Verzenio projected flat or down in 2026.
  • Novo Nordisk's oral Wegovy approval may erode Lilly market share before forglipron launches Q2 2026.
  • Rising GLP-1 competition threatens growth trajectories for Mounjaro and Zepbound.
  • AbbVie expects $31B combined 2026 sales to miss both own and 2027 guidance.
Bullish Signals
  • AbbVie successfully navigated Humira loss of exclusivity by launching two highly successful immunology medicines, Skyrizi and Rinvoq, which generated combined sales of $26.0 billion in 2025 with year-over-year growth of more than 40%.
  • In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion, exceeding its long-term guidance targets and signaling strong product momentum.
  • AbbVie's neuroscience portfolio contributed robust growth with sales increasing almost 20% to $10.8 billion in 2025, driven by Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta.
  • The oncology segment generated combined revenues of $6.6 billion in 2025, up 1.5% year over year, supported by higher sales of Venclexta and new drugs Elahere and Epkinly.
  • AbbVie has invested more than $5 billion in 2025 on acquisitions to bolster its early-stage pipeline in immunology, oncology, and neuroscience areas for long-term growth.
  • Eli Lilly expects its new drug portfolio including Mounjaro, Zepbound, Ebglyss, Jaypirca, Kisunla, Omvoh, and Inluriyo to drive sales growth in 2026.
  • Lilly secured approvals for several new therapies such as Omvoh, Jaypirca, Ebglyss and Kisunla over the past few years, all contributing to revenue expansion.
  • Lilly's once-daily oral GLP-1 small molecule orforglipron is expected to launch in the United States during the second quarter of 2026, offering a convenient alternative to injectable treatments.
  • AbbVie and Lilly both maintain strong R&D pipelines, significant market capitalizations, and extensive global reach across key therapeutic areas like immunology, oncology, and neuroscience.
Risk Factors
  • Lilly faces a significant headwind from declining product prices in the United States, with price erosion expected to continue dragging on top-line growth by a low to mid-teens percentage in 2026.
  • Sales of late-life cycle products including Trulicity, Taltz, and Verzenio are projected to be flat or decline in 2026 as competition intensifies.
  • Novo Nordisk's approval of an oral version of Wegovy in December 2025 gives the rival first-to-market advantage, potentially eroding Lilly's market share and revenues before its own oral obesity pill, orforglipron, launches in the second quarter of 2026.
  • Rising competition in the GLP-1 diabetes and obesity market is identified as a key headwind that could impact growth trajectories for Lilly's blockbuster Mounjaro and Zepbound.
  • AbbVie may face revenue challenges despite strong Skyrizi and Rinvoq sales, as it expects 2026 combined sales of $31 billion to fall short of its own long-term guidance, which also stands at $31 billion for 2027.
Bullish +75

Market Downturn: 2 Stocks to Buy and Hold Through Any Storm

The article argues that AbbVie (NYSE: ABBV) is a strong defensive investment suitable for holding during market downturns, citing its resilient business model and deep product pipeline. The text explains that AbbVie's vast portfolio of medicines for chronic autoimmune conditions and cancer maintains consistent revenue even if prescription volumes soften in an economic slowdown. Furthermore, the company utilizes a robust development pipeline to successfully navigate the "patent cliff," ensuring long-term value creation despite losing protection on older blockbuster drugs. A key highlight of the investment case is AbbVie's status as a Dividend King, having increased its payout for over 50 consecutive years. The article emphasizes that this streak indicates management's commitment to maintaining dividends even during challenging times, which can help smooth out losses for investors when equity markets crash. While it warns against speculative biotechs, it positions AbbVie as a high-quality, resilient option distinct from companies with no products or consistent net losses. The piece contextualizes these points by also recommending Microsoft (NASDAQ: MSFT) as a similarly defensive technology stock due to its entrenched software products and strong credit rating. It notes that while Azure growth could moderate in a recession, the company's leadership in cloud computing and AI offers attractive long-term prospects for patient investors who might buy at a discount. The article concludes with an advertisement segment from The Motley Fool Stock Advisor, which claims their 10 best stocks list did not include AbbVie despite their team holding a position in the company. It uses historical examples of Netflix and Nvidia to illustrate the potential returns of following their specific picks, ultimately urging readers to consider joining their community for updated recommendations.

⚠ Defensive pharma and tech stocks are highlighted for stability during market volatility.

💊💻 AbbVie offers patent diversification while Microsoft provides reliable recurring revenue from productivity tools.

🏆 The Motley Fool's Stock Advisor has historically delivered massive returns significantly outperforming the S&P 500.

📉 Markets face volatility due to geopolitical tensions and tariff uncertainty, prompting investors to seek defensive assets.

💊 AbbVie is highlighted as a resilient pharmaceutical stock with a strong portfolio in chronic autoimmune conditions and cancer therapies.

🛡️ Pharma stocks are generally considered defensive because demand for essential medicines remains stable during economic slowdowns.

🔄 AbbVie has a deep product pipeline that helps mitigate risks associated with patent cliff expiration.

👑 The company is a "Dividend King," having increased its dividend payouts for 50 consecutive years, which helps smooth investor losses during downturns.

💻 Microsoft is presented as a defensive tech stock due to its entrenched products like Office used daily by individuals and businesses.

☁️ While Azure is a growth engine, the company maintains consistent revenue from productivity tools even if clients tighten budgets in a recession.

⭐ Microsoft holds an Aaa credit rating, which is higher than that of the U.S. government, signaling rock-solid financial health.

📈 Investors may buy Microsoft at a discount during downturns, expecting it to recover and deliver superior long-term returns as before.

⚠️ AbbVie was notably excluded from The Motley Fool's current list of top 10 stocks recommended by the Stock Advisor team.

🏆 The Stock Advisor report highlights massive historical returns for past picks like Netflix (52x return) and Nvidia (113x return).

📊 The average total return for the Stock Advisor service is reported at 952%, significantly outperforming the S&P 500's 191%.

⏳ All Stock Advisor returns cited are noted as of March 11, 2026.

🧑‍💼 Prosper Junior Bakiny holds no position in the mentioned stocks, while The Motley Fool itself recommends AbbVie and Microsoft.

Bullish Signals
  • AbbVie (NYSE: ABBV) is a 'Dividend King' with 50 years of payout increases.
  • Its portfolio targets resilient chronic autoimmune and cancer markets.
  • A deep pipeline offers strategies to navigate the patent cliff.
  • As a defensive stock, it generates consistent revenue during volatility.
Risk Factors
  • Equity market volatility fears persist amid geopolitical tensions and tariff uncertainty.
  • AbbVie excluded from Motley Fool's top 10 stocks list.
  • Dividends may not offset losses during severe market crashes.
  • Azure growth could moderate if clients tighten recession budgets.
  • Microsoft may fall sharply with the broader market in a downturn.
  • AbbVie prescription volumes may soften during challenging economic periods.
Bullish Signals
  • AbbVie (NYSE: ABBV) is highlighted as a 'Dividend King' with 50 straight years of payout increases, providing income stability during market downturns.
  • The company possesses a vast pharmaceutical portfolio focused on chronic autoimmune conditions and cancer, sectors which tend to remain resilient even when prescription volumes soften.
  • AbbVie has a deep pipeline that allows it to develop and launch new products, offering a strategic way to navigate the patent cliff.
  • As a defensive stock, AbbVie is positioned to generate consistent revenue and earnings even during severe economic problems or market volatility.
  • The Motley Fool has identified AbbVie as a top stock for investors to prepare for a market downturn, specifically noting its defensive nature against cyclical exposure.
Risk Factors
  • Equity markets have been volatile this year, with some fear the stock market could take a turn for the worse by the end of the year amid geopolitical tensions and lingering tariff-related uncertainty.
  • The article explicitly states that AbbVie was not included in the Motley Fool Stock Advisor's list of 10 best stocks to buy now, potentially implying it is not among their top tier of high-conviction picks.
  • While AbbVie's dividend status as a Dividend King is noted as positive, dividends may not be sufficient to offset losses if the company faces severe challenges or market crashes that impact its payout ability.
  • Microsoft's Azure segment could see growth moderate if clients tighten budgets during a recession, indicating potential downside pressure on its primary growth engine.
  • The article acknowledges that Microsoft is unlikely to emerge entirely unscathed from an economic downturn, with the possibility of falling sharply along with the rest of the market before recovering.
  • Prescription volumes for AbbVie may soften during challenging periods, which could impact consistent revenue generation despite strong demand in specific therapeutic areas.